According to Zacks, “Inovio, a development-stage biopharmaceutical company, is focused on the development of treatments targeting various cancer forms and infectious diseases. Inovio received a huge setback when Roche decided to discontinue its collaboration with the company for the development of hepatitis B DNA immunotherapy, INO-1800. Following the decision, the company has resolved to develop INO-1800 independently. We note that being a development-stage company, Inovio depends largely on government grants and contracts for the development of its candidates. Thus, inability to secure sufficient funding could hinder its pipeline progress. Moreover, most of Inovio’s pipeline candidates are in early stages of development and thus, quite a few years away from entering the market, if at all. However, we are positive on the company’s progress with its lead cancer candidate, VGX-3100, which is expected to move into a late-stage study late in 2016.”
Several other analysts have also recently weighed in on the stock. HC Wainwright assumed coverage on shares of Inovio Pharmaceuticals in a report on Monday, August 29th. They issued a buy rating and a $17.00 target price on the stock. Maxim Group reiterated a hold rating on shares of Inovio Pharmaceuticals in a research note on Thursday, August 18th. Brean Capital set a $18.00 price target on shares of Inovio Pharmaceuticals and gave the company a buy rating in a research note on Monday, August 8th. Piper Jaffray Cos. reiterated an overweight rating and issued a $31.00 price target on shares of Inovio Pharmaceuticals in a research note on Monday, August 8th. Finally, Vetr lowered shares of Inovio Pharmaceuticals from a strong-buy rating to a buy rating and set a $11.11 price target on the stock. in a research note on Monday, August 1st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the stock. Inovio Pharmaceuticals presently has a consensus rating of Buy and a consensus price target of $16.39.
Inovio Pharmaceuticals (NASDAQ:INO) opened at 9.74 on Tuesday. The firm’s market capitalization is $716.36 million. The company has a 50 day moving average of $9.11 and a 200 day moving average of $9.38. Inovio Pharmaceuticals has a 1-year low of $4.50 and a 1-year high of $11.69.
Inovio Pharmaceuticals (NASDAQ:INO) last issued its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by $0.05. The firm earned $6.20 million during the quarter, compared to analyst estimates of $4.95 million. Inovio Pharmaceuticals had a negative net margin of 88.19% and a negative return on equity of 22.29%. The firm’s revenue was up 17.0% compared to the same quarter last year. During the same period last year, the business earned ($0.09) EPS. Analysts forecast that Inovio Pharmaceuticals will post ($0.93) EPS for the current year.
In other news, Director Morton Collins acquired 10,000 shares of the stock in a transaction that occurred on Tuesday, June 28th. The shares were purchased at an average cost of $9.13 per share, for a total transaction of $91,300.00. Following the transaction, the director now directly owns 142,291 shares in the company, valued at approximately $1,299,116.83. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Niranjan Sardesai sold 21,800 shares of Inovio Pharmaceuticals stock in a transaction on Monday, August 29th. The shares were sold at an average price of $9.30, for a total transaction of $202,740.00. Following the completion of the transaction, the chief operating officer now owns 70,234 shares in the company, valued at $653,176.20. The disclosure for this sale can be found here. Insiders own 9.90% of the company’s stock.
A number of institutional investors have recently bought and sold shares of INO. BlackRock Group LTD raised its position in Inovio Pharmaceuticals by 71.1% in the first quarter. BlackRock Group LTD now owns 22,064 shares of the biopharmaceutical company’s stock worth $192,000 after buying an additional 9,168 shares during the period. BlackRock Fund Advisors increased its stake in Inovio Pharmaceuticals by 1.4% in the first quarter. BlackRock Fund Advisors now owns 2,804,668 shares of the biopharmaceutical company’s stock worth $24,429,000 after buying an additional 37,732 shares during the period. Geode Capital Management LLC increased its stake in Inovio Pharmaceuticals by 10.3% in the first quarter. Geode Capital Management LLC now owns 481,434 shares of the biopharmaceutical company’s stock worth $4,193,000 after buying an additional 44,923 shares during the period. Legal & General Group Plc increased its stake in Inovio Pharmaceuticals by 10.0% in the first quarter. Legal & General Group Plc now owns 13,204 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 1,205 shares during the period. Finally, Bellevue Group AG acquired a new stake in Inovio Pharmaceuticals during the first quarter worth approximately $2,308,000. Hedge funds and other institutional investors own 28.58% of the company’s stock.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc (Inovio) is a bio-pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.